GCG and type 2 diabetes mellitus: In the outpatient setting, GLP‐1 receptor agonists (GLP‐1 RA) are considered to provide effective glycaemic control, weight loss, and cardiovascular benefits with a low risk of hypoglycaemia.1, 2 The use of GLP‐1 RA have increased rapidly and are now recommended for use as second‐line therapy for type 2 diabetes (T2DM).3 As a result, individuals treated with GLP‐1 RA will be more frequently encountered at the inpatient setting.